Several brokerages have updated their recommendations and price targets on shares of G1 Therapeutics (NASDAQ: GTHX) in the last few weeks:

  • 5/15/2019 – G1 Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $27.00 price target on the stock. According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
  • 5/10/2019 – G1 Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 5/7/2019 – G1 Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
  • 5/7/2019 – G1 Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 4/4/2019 – G1 Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
  • 3/30/2019 – G1 Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 3/28/2019 – G1 Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
  • 3/22/2019 – G1 Therapeutics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 3/20/2019 – G1 Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “

G1 Therapeutics stock traded down $1.08 during mid-day trading on Thursday, hitting $22.69. The stock had a trading volume of 9,255 shares, compared to its average volume of 336,147. The company has a market capitalization of $890.59 million, a P/E ratio of -8.86 and a beta of 2.50. G1 Therapeutics Inc has a one year low of $13.87 and a one year high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last issued its earnings results on Thursday, May 9th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.05. As a group, analysts anticipate that G1 Therapeutics Inc will post -2.99 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of GTHX. Hillhouse Capital Advisors Ltd. bought a new position in G1 Therapeutics in the 4th quarter worth $18,182,000. Wellington Management Group LLP boosted its holdings in G1 Therapeutics by 23.0% in the 1st quarter. Wellington Management Group LLP now owns 4,636,474 shares of the company’s stock worth $76,966,000 after buying an additional 866,859 shares during the period. Vanguard Group Inc boosted its holdings in G1 Therapeutics by 76.3% in the 3rd quarter. Vanguard Group Inc now owns 1,717,733 shares of the company’s stock worth $89,821,000 after buying an additional 743,596 shares during the period. Vanguard Group Inc. boosted its holdings in G1 Therapeutics by 76.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,717,733 shares of the company’s stock worth $89,821,000 after buying an additional 743,596 shares during the period. Finally, FMR LLC boosted its holdings in G1 Therapeutics by 6.9% in the 4th quarter. FMR LLC now owns 5,577,754 shares of the company’s stock worth $106,814,000 after buying an additional 361,091 shares during the period. 73.47% of the stock is owned by institutional investors.

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Featured Article: How is the S&P 500 index different from the DJIA?

Receive News & Ratings for G1 Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.